Treatment of New-Onset Atrial Fibrillation with Rapid Ventricular Response of Unknown Onset

Immediate Assessment and Management

For new-onset AFib with RVR of unknown onset, the European Society of Cardiology recommends immediately assessing hemodynamic stability, and if unstable, performing emergent electrical cardioversion, while if stable, initiating rate control with IV beta-blockers or non-dihydropyridine calcium channel blockers as first-line agents, and ensuring therapeutic anticoagulation for at least 3 weeks before any elective cardioversion or performing TEE to exclude thrombus if earlier cardioversion is desired 1, 2
Hemodynamically unstable patients require immediate electrical cardioversion, according to the European Heart Journal 1
The American Heart Association suggests that stable patients proceed to a rate control strategy, as stated in Circulation 1
When assessing for contraindications to standard rate control, it is crucial to check for pre-excitation (WPW syndrome) on ECG, and if present, avoid AV nodal blocking agents, as recommended by the American College of Cardiology 3, 2
Evaluating left ventricular function (LVEF) is essential, as it determines drug selection, according to the European Heart Journal 1
Identifying heart failure with reduced ejection fraction (HFrEF, LVEF ≤40%) is vital, as stated in Circulation 3

For patients with LVEF >40% (preserved function), the European Society of Cardiology recommends beta-blockers (metoprolol, esmolol) or diltiazem or verapamil as first-choice drugs 1
For patients with LVEF ≤40% (reduced function), the American College of Cardiology recommends beta-blockers and/or digoxin, while avoiding non-dihydropyridine calcium channel blockers (diltiazem, verapamil), which is a Class III (Harm) recommendation 1, 3, 4
IV amiodarone is recommended when other measures are unsuccessful or contraindicated, as stated in Circulation 3, 5

Since onset timing is unknown, assuming duration >24 hours and high thromboembolic risk, the European Heart Journal recommends therapeutic oral anticoagulation for at least 3 weeks before cardioversion, with direct oral anticoagulants (DOACs) preferred over warfarin 1
For warfarin, INR ≥2.0 must be documented, according to the European Heart Journal 1
The American Heart Association suggests performing transesophageal echocardiography (TEE) to exclude left atrial thrombus before early cardioversion, as stated in Circulation 1, 2
Post-cardioversion anticoagulation should be continued for at least 4 weeks after cardioversion in all patients, as recommended by the European Society of Cardiology 1

For structurally normal hearts, the European Heart Journal recommends IV flecainide or propafenone (Class I recommendation) for pharmacological cardioversion 1
For patients with structural heart disease, IV amiodarone is recommended, accepting delayed cardioversion, according to the European Heart Journal 1
Electrical cardioversion is recommended for hemodynamically unstable patients, as stated in the European Heart Journal 1

The American College of Cardiology advises never using calcium channel blockers in decompensated heart failure or LVEF ≤40%, as this worsens hemodynamics 3, 4
Never cardiovert without 3 weeks anticoagulation or TEE when AF duration >24 hours or unknown, as recommended by the European Heart Journal 1
Avoid AV nodal blockers in pre-excitation syndromes (WPW), as they can precipitate ventricular fibrillation, according to Circulation 3, 2
Do not use beta-blockers in overt hypotension or decompensated heart failure, as stated in Circulation 3, 4

If pharmacological rate control fails, the American Heart Association suggests considering AV node ablation with ventricular pacing as a reasonable option when medications are insufficient or not tolerated 3, 5